Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
14 Jul 2023
Historique:
received: 11 08 2022
accepted: 18 01 2023
medline: 17 7 2023
pubmed: 21 1 2023
entrez: 20 1 2023
Statut: ppublish

Résumé

Most observational population-based studies identify respiratory syncytial virus (RSV) by nasal/nasopharyngeal swab reverse transcriptase real-time PCR (RT-PCR) only. We conducted a systematic review and meta-analyses to quantify specimen and diagnostic testing-based underascertainment of adult RSV infection. EMBASE, PubMed, and Web of Science were searched (January 2000-December 2021) for studies including adults using/comparing >1 RSV testing approach. We quantified test performance and RSV detection increase associated with using multiple specimen types. Among 8066 references identified, 154 met inclusion. Compared to RT-PCR, other methods were less sensitive: rapid antigen detection test (RADT; pooled sensitivity, 64%), direct fluorescent antibody (DFA; 83%), and viral culture (86%). Compared to singleplex PCR, multiplex PCR's sensitivity was lower (93%). Compared to nasal/nasopharyngeal swab RT-PCR alone, adding another specimen type increased detection: sputum RT-PCR, 52%; 4-fold rise in paired serology, 44%; and oropharyngeal swab RT-PCR, 28%. Sensitivity was lower in estimates limited to only adults (for RADT, DFA, and viral culture), and detection rate increases were largely comparable. RT-PCR, particularly singleplex testing, is the most sensitive RSV diagnostic test in adults. Adding additional specimen types to nasopharyngeal swab RT-PCR testing increased RSV detection. Synergistic effects of using ≥3 specimen types should be assessed, as this approach may improve the accuracy of adult RSV burden estimates. Respiratory syncytial virus (RSV) is an important cause of illness and death among older adults. Most studies of how frequent RSV infection is among older adults use only nasal swab testing to identify RSV infection. These nasal swabs are checked for genetic material from the virus, known as polymerase chain reaction (PCR) testing. We examined published studies from January 2000 to December 2021 to estimate how many RSV infections would be missed by using only this approach to RSV testing. We found 154 studies had information to answer our question. Compared to PCR testing of nasal swab alone, adding sputum specimen PCR testing (ie, testing cough mucus or phlegm for RSV genetic material) increased RSV infections found by 52%. Adding blood testing increased RSV infections found by 44%. Adding mouth/throat swab PCR testing, increased RSV infections by 28%. In summary, adding additional specimen types to nasal swab PCR testing increased RSV detection. Impact of using 3 or more specimen types at the same time should be assessed, as this approach may further improve accuracy.

Sections du résumé

BACKGROUND BACKGROUND
Most observational population-based studies identify respiratory syncytial virus (RSV) by nasal/nasopharyngeal swab reverse transcriptase real-time PCR (RT-PCR) only. We conducted a systematic review and meta-analyses to quantify specimen and diagnostic testing-based underascertainment of adult RSV infection.
METHODS METHODS
EMBASE, PubMed, and Web of Science were searched (January 2000-December 2021) for studies including adults using/comparing >1 RSV testing approach. We quantified test performance and RSV detection increase associated with using multiple specimen types.
RESULTS RESULTS
Among 8066 references identified, 154 met inclusion. Compared to RT-PCR, other methods were less sensitive: rapid antigen detection test (RADT; pooled sensitivity, 64%), direct fluorescent antibody (DFA; 83%), and viral culture (86%). Compared to singleplex PCR, multiplex PCR's sensitivity was lower (93%). Compared to nasal/nasopharyngeal swab RT-PCR alone, adding another specimen type increased detection: sputum RT-PCR, 52%; 4-fold rise in paired serology, 44%; and oropharyngeal swab RT-PCR, 28%. Sensitivity was lower in estimates limited to only adults (for RADT, DFA, and viral culture), and detection rate increases were largely comparable.
CONCLUSIONS CONCLUSIONS
RT-PCR, particularly singleplex testing, is the most sensitive RSV diagnostic test in adults. Adding additional specimen types to nasopharyngeal swab RT-PCR testing increased RSV detection. Synergistic effects of using ≥3 specimen types should be assessed, as this approach may improve the accuracy of adult RSV burden estimates.
Respiratory syncytial virus (RSV) is an important cause of illness and death among older adults. Most studies of how frequent RSV infection is among older adults use only nasal swab testing to identify RSV infection. These nasal swabs are checked for genetic material from the virus, known as polymerase chain reaction (PCR) testing. We examined published studies from January 2000 to December 2021 to estimate how many RSV infections would be missed by using only this approach to RSV testing. We found 154 studies had information to answer our question. Compared to PCR testing of nasal swab alone, adding sputum specimen PCR testing (ie, testing cough mucus or phlegm for RSV genetic material) increased RSV infections found by 52%. Adding blood testing increased RSV infections found by 44%. Adding mouth/throat swab PCR testing, increased RSV infections by 28%. In summary, adding additional specimen types to nasal swab PCR testing increased RSV detection. Impact of using 3 or more specimen types at the same time should be assessed, as this approach may further improve accuracy.

Autres résumés

Type: plain-language-summary (eng)
Respiratory syncytial virus (RSV) is an important cause of illness and death among older adults. Most studies of how frequent RSV infection is among older adults use only nasal swab testing to identify RSV infection. These nasal swabs are checked for genetic material from the virus, known as polymerase chain reaction (PCR) testing. We examined published studies from January 2000 to December 2021 to estimate how many RSV infections would be missed by using only this approach to RSV testing. We found 154 studies had information to answer our question. Compared to PCR testing of nasal swab alone, adding sputum specimen PCR testing (ie, testing cough mucus or phlegm for RSV genetic material) increased RSV infections found by 52%. Adding blood testing increased RSV infections found by 44%. Adding mouth/throat swab PCR testing, increased RSV infections by 28%. In summary, adding additional specimen types to nasal swab PCR testing increased RSV detection. Impact of using 3 or more specimen types at the same time should be assessed, as this approach may further improve accuracy.

Identifiants

pubmed: 36661222
pii: 6994132
doi: 10.1093/infdis/jiad012
pmc: PMC10345483
doi:

Types de publication

Systematic Review Meta-Analysis Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-184

Subventions

Organisme : Pfizer Inc

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. P95 was contracted by Pfizer to conduct this study. C. O., L. M. M., S. M., B. M., M. S., N. A., M. R., Z. A.-T., and H. V. are employees of P95. D. C., W. K., J. E. A., B. D. G., M. R., and E. B. are employees of Pfizer and may hold stock or stock options. H. N. declares no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Références

J Clin Microbiol. 2014 Aug;52(8):3057-9
pubmed: 24850350
Clin Microbiol Infect. 2019 Mar;25(3):372-378
pubmed: 29906597
J Clin Microbiol. 2009 Nov;47(11):3439-43
pubmed: 19726607
Eur Respir J. 2021 Apr 1;57(4):
pubmed: 33060153
J Virol Methods. 2019 Jul;269:49-54
pubmed: 30946852
J Med Virol. 2019 Jan;91(1):65-71
pubmed: 30132922
J Clin Microbiol. 2007 Feb;45(2):604-6
pubmed: 17182755
Clin Infect Dis. 2012 Apr;54(7):905-12
pubmed: 22238168
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
J Clin Microbiol. 2012 Jan;50(1):21-4
pubmed: 22090400
J Infect Dis. 2022 Aug 12;226(Suppl 1):S63-S70
pubmed: 35134954
Fam Pract. 2017 Sep 1;34(5):558-563
pubmed: 28369370
Clin Vaccine Immunol. 2013 Jan;20(1):113-4
pubmed: 23114699
Diagn Microbiol Infect Dis. 2008 Sep;62(1):44-51
pubmed: 18639996
J Clin Microbiol. 2016 Dec 28;55(1):79-89
pubmed: 27795341
J Clin Virol. 2003 Apr;26(3):339-46
pubmed: 12637083
J Virol Methods. 2015 Mar;213:131-4
pubmed: 25500182
J Clin Microbiol. 2002 Mar;40(3):817-20
pubmed: 11880399
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
J Infect Dis. 2013 May 1;207(9):1424-32
pubmed: 23382572
Clin Med Res. 2012 Nov;10(4):215-8
pubmed: 22723469
Clin Infect Dis. 2010 Mar 1;50(5):747-51
pubmed: 20121411
J Clin Microbiol. 2015 Dec;53(12):3738-49
pubmed: 26354816
J Med Virol. 2016 Oct;88(10):1720-4
pubmed: 26990654
Emerg Microbes Infect. 2017 Jun 7;6(6):e49
pubmed: 28588283
Infect Dis (Lond). 2021 Aug;53(8):581-589
pubmed: 33760699
PLoS One. 2011;6(6):e21610
pubmed: 21738731
Diagn Microbiol Infect Dis. 2015 Nov;83(3):252-6
pubmed: 26283523
J Med Virol. 2014 Dec;86(12):2122-7
pubmed: 24797344
Scand J Infect Dis. 2014 Dec;46(12):825-31
pubmed: 25195649
Open Microbiol J. 2011;5:128-34
pubmed: 22262985
Pediatr Infect Dis J. 2007 Nov;26(11 Suppl):S36-40
pubmed: 18090198
J Med Virol. 2020 Jul 29;:
pubmed: 32725889
J Med Virol. 2005 Feb;75(2):336-47
pubmed: 15602736
J Clin Microbiol. 2001 Aug;39(8):2779-83
pubmed: 11473991
J Clin Virol. 2016 Apr;77:1-4
pubmed: 26872325
J Clin Microbiol. 2006 Jul;44(7):2382-8
pubmed: 16825353
J Clin Microbiol. 2014 Oct;52(10):3590-6
pubmed: 25056335
J Virol Methods. 2012 Jun;182(1-2):82-6
pubmed: 22465255
J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583
pubmed: 30880339
Open Forum Infect Dis. 2022 Jun 17;9(7):ofac300
pubmed: 35873302
Vaccine. 2018 May 31;36(23):3199-3207
pubmed: 29716771
Oncotarget. 2017 Jun 17;8(57):96913-96923
pubmed: 29228581
Infect Dis (Lond). 2019 Apr;51(4):241-248
pubmed: 30760088
BMJ. 2020 Aug 14;370:m2632
pubmed: 32816740
Arch Virol. 2014 Apr;159(4):669-76
pubmed: 24126621

Auteurs

Chukwuemeka Onwuchekwa (C)

P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.

Laura Mora Moreo (LM)

P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.

Sonia Menon (S)

P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.

Belen Machado (B)

P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.

Daniel Curcio (D)

Pfizer Vaccine, Ireland.

Warren Kalina (W)

Pfizer Vaccine, Ireland.

Jessica E Atwell (JE)

Pfizer Vaccine, Ireland.

Bradford D Gessner (BD)

Pfizer Vaccine, Ireland.

Mariana Siapka (M)

P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Impact Epilysis, Thessaloniki, Greece.

Neha Agarwal (N)

P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.

Michelle Rubbrecht (M)

P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.

Harish Nair (H)

Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.

Mark Rozenbaum (M)

Pfizer Inc, Capelle aan den Ijssel, The Netherlands.

Zuleika Aponte-Torres (Z)

P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.

Hilde Vroling (H)

P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH